Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Peranteau

Dermatology New York, NY Medical Doctor

NPI 1588075386 CMS profile 1120244

214 Sullivan St, New York, NY 10012

Open in the dashboard

General payments

$30,539

500 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$715,635 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Andrew Peranteau of New York, NY is reported in the CMS Open Payments database as having received $30,539 across 500 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $715,635 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,561 162
2024 General $5,845 95
2023 General $2,469 99
2022 General $2,069 78
2021 General $1,166 54
2020 General $198 10
2019 General $231 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Peranteau
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Andrew Peranteau were reported at $18,561. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Andrew Peranteau Dermatology median Middle half National median
2019 $231 $454 $129–$1,240 $163
2020 $198 $235 $81–$756 $114
2021 $1,166 $377 $108–$1,108 $132
2022 $2,069 $514 $143–$1,391 $149
2023 $2,469 $607 $159–$1,674 $160
2024 $5,845 $751 $204–$1,903 $164
2025 $18,561 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $20,937 125 payments
  2. Janssen Biotech, Inc. $982 40 payments
  3. Regeneron Healthcare Solutions, Inc. $878 23 payments
  4. Pfizer Inc. $832 39 payments
  5. UCB, Inc. $819 26 payments
  6. Lilly USA, LLC $758 39 payments
  7. Novartis Pharmaceuticals Corporation $660 28 payments
  8. Sun Pharmaceutical Industries Inc. $589 23 payments
  9. LEO Pharma Inc. $574 26 payments
  10. Journey Medical Corporation $517 10 payments
  11. Other $2,992 121 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,950 6 payments
  2. Food and Beverage $12,510 489 payments
  3. Consulting Fee $2,275 1 payment
  4. Travel and Lodging $599 1 payment
  5. Education $205 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $19,746 75 payments
  2. TREMFYA $1,107 41 payments
  3. SKYRIZI $956 42 payments
  4. TALTZ $734 38 payments
  5. Bimzelx $640 18 payments
  6. COSENTYX $488 19 payments
  7. OPZELURA $455 16 payments
  8. ADBRY $454 20 payments
  9. DUPIXENT Immunology $429 20 payments
  10. DUPIXENT Inflammation And Immunology $426 13 payments
  11. Other $5,583 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

480

Median for Dermatology: 534

Drug cost

$44,584

Median for Dermatology: $67,151

Branded share of claims

5.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 14 $27,486
Acitretin Generic 11 $3,190
Tretinoin Generic 34 $2,579
Clobetasol Propionate Generic 40 $1,849
Metronidazole Generic 19 $1,648
Halobetasol Propionate Generic 25 $1,643
Clindamycin Phosphate Generic 29 $1,177
Ketoconazole Generic 95 $1,134
Ammonium Lactate Generic 40 $806
Ciclopirox Ciclopirox Olamine Brand 11 $764

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$44,034

Of which drugs: $22

Medicare patients

162

Average age 70

Services billed

630

89 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 46%
Diabetes 31%
Ischemic heart disease 26%
Depression 20%
Osteoporosis 17%
Chronic kidney disease 15%
COPD 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $3,895
$3,895 — —
Bimzelx
  • UCB, Inc. $286
$286 — —
SKYRIZI
  • AbbVie, Inc. $259
$259 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $251
$251 — —
DUPIXENT
  • GENZYME CORPORATION $100
  • Regeneron Healthcare Solutions, Inc. $98
$197 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

500 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record